Navigation Links
Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology
Date:11/26/2013

SYDNEY, Nov. 26, 2013 /PRNewswire/ -- Novogen Limited (ASX: symbol NRT; Nasdaq: symbol NVGN) today announced the filing of a family of provisional patents in the US covering anti-tropomyosin (ATM) drug technology.

ATM drugs represent an entirely novel approach to anti-cancer therapy, blocking the ability of cancer cells to divide and doing so in a highly cancer-specific way. Based on their action, ATMs belong to a class of anti-cancer drug known as anti-mitotics. Current anti-mitotic drugs are taxanes and vinca alkaloids and remain among the most widely prescribed anti-cancer drugs after 40 years of use.

"Filing these patents represents a critical step for the Company in protecting such a potentially valuable piece of intellectual property," said Graham Kelly, PhD, Novogen CEO. "Taxanes continue to dominate anti-cancer therapy even though they recently came off-patent. We believe that ATM drugs have the ability to replace taxanes and to become the next generation of anti-mitotic drugs."

Tropomyosin is a protein found in actin filaments, a key component of the cytoskeleton of a cell. Actin filaments provide a cell with the ability to contract. One of the ways that contraction serves a cell is during cell division when separation of the two daughter cells occurs by the formation of a ring known as the contraction ring. When that ring tightens, the two cells effectively separate.

ATM drugs target a particular isoform of tropomyosin known as Tm5NM1 on which cancer cells are highly dependent. Targeting this particular tropomyosin isoform prevents formation of the contraction ring and hence the ability of the cancer cells to divide.

"The current generation of anti-mitotic drugs, despite their widespread use, comes with two key negatives," Dr. Kelly added. "The first of those is a serious side-effect profile. The second is that many types of cancer are inherently insensitive to them. ATM drugs to date are showing an apparent lack of serious toxicity as well as an ability to kill cancer cells that are insensitive to taxanes."

Novogen is focusing its ATM drug development program on prostate cancer, melanoma and children's cancers where it would be used as a monotherapy, as well as adjuvant therapy in combination with the Company's super-benzopyran drug technology in order to provide comprehensive assault on the full hierarchy of cells within tumors.

About Novogen
Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol 'NRT') and NASDAQ (symbol 'NVGN').  The Company is based in Sydney, Australia and is focused on the development of novel anti-cancer drugs based on two proprietary drug technologies - the super-benzopyran chemical family and anti-tropomyosin drug technology.

Tm5NM1
Tm5NM1 is one of approximately 40 different isoforms of the protein, tropomyosin, that occur naturally in the human body. Tropomyosins combine with the protein, actin, to form actin filaments, making up part of the cell's cytoskeleton. Human cancer cells have been shown to be highly dependent on Tm5NM1 for their survival and ability to divide.

About Super-Benzopyrans (SBPs)
SBPs are small molecules constructed around a simple benzopyran scaffold. Members of this family of drugs are showing high potency against both cancer stem cells and somatic cancer cells recovered from both ovarian cancers and glioblastoma cancers.


'/>"/>
SOURCE Novogen Limited
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer
2. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
3. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
4. Envera Files Patent for Low Temperature Growing Bacteria
5. MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of MCT-485, a Noncoding miRNA for Cancer Treatment
6. InspireMD Files At-the-Market Offering and Shelf Registration Statement
7. Polaris Group Files New IND for ADI-PEG 20 in Breast Cancer
8. Veracyte, Inc. Files Registration Statement for Initial Public Offering
9. PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission
10. Adheris Inc. Files For Preliminary Injunction To Stop U.S. Government From Infringing On Constitutionally Protected Speech
11. Perrigo Files Registration Statement On Form S-4 In Connection With Proposed Acquisition Of Elan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs ... the Prince Of Wales Private Hospital. The procedure was performed on a 46-year-old ... failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is ...
(Date:5/18/2017)... ... ... Clinical Supplies Management (“CSM”), a Great Point Partners II (“GPP”) portfolio company, today ... doubled in size over the past six months with the acquisition of businesses in ... CSM as Chief Financial Officer. Roger has over 25 years of experience in ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... expertise, and further enhances its scientific power by providing investigators access to ... has agreed to join the scientific advisory board. “We are committed to ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... optimization firm for the life sciences and healthcare industries, is honored that ... for Medical Devices conference in Brussels, Belgium. , Crowley played a crucial role ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
Breaking Biology News(10 mins):